Amylin's Eastham Says Eastbourne's Behrens Is Not Telling the Truth About $20 Share Bid
Amylin director Karin Eastham has, in essence, called Eastbourne Capital board candidate M. Kathleen Behrens a liar (or at least an amnesiac).
On May 11, Behrens had written to Amylin decrying the company's "baseless accusation[s]" and "innuendo"; she alleged Amylin was spreading a rumor that she wanted to see Amylin acquired by another company at $20 a share. Behrens insisted that she wants no such thing.
Today, Eastham wrote back to Behrens to say, Yeah, you did say that:
You may recall that you and I had a phone conversation on January 22, 2009 ... During that conversation, we discussed the topic of a potential sale of the Company and you expressed an interest and willingness to sell Amylin at a price of $20 a share ...Amylin is attempting to fend off a challenge for control of its board by Eastbourne and investor Carl Icahn; both believe the company's stock has fallen too low. A shareholder vote is scheduled for the end of this month.I listened very carefully to your perspective and respectfully assure you that you did in fact state your willingness to sell Amylin for $20 a share.
- See previous coverage of Amylin:
- Amylin Accused of Spreading "Baseless Accusations," "Innuendo" and Misusing CNBC in Director Fight
- Amylin Sales Force Is Least-Effective Among Its Peers, Claims Eastbourne
- Amylin May Abandon the "Byetta" Name for Exenatide Once Weekly
- Amylin v. Icahn Slideshow Battle: Tear Up Lilly-Byetta Agreement!
- Amylin v. Eastbourne Slideshow Battle; It's All About the Stock Price
- In U-Turn, Amylin Lays Off 200; Move Validates Icahn's Arguments
- Amylin Trial Testimony: Debt Not Structured With Interest or Principal Payments in Mind
- The War for Amylin: Lilly Not Interested; Icahn Calls the Company a "Dictatorship"
- Amylin CEO Got 11% Pay Rise Despite Losses; Company Paid $355K for Lawyer to Move House
- Amylin Q1: "Icahn Doesn't Know Who Our CEO Is"
- In War for Amylin, Icahn and Eastbourne Win a Battle: "Poison Pill" Revoked
- Amylin Founder Resigns, Suggests Chairman Follow; Icahn and Eastbourne Likely Delighted
- Inside Amylin's Anti-Icahn Suicide Pact
- Amylin Battle Heats Up as Eastbourne Capital Touts Rival Directors' Slate to Icahn's
- Icahn Moves on Amylin; Will Lilly Step Up?
- Behind the Byetta Crisis: Is This Drug Really All That and a Bag of (Fat-Free) Chips?